The Food and Drug Administration has approved the first biosimilar for the treatment of non-Hodgkin lymphoma. A biosimilar is a medication that is similar to a biologic, which is a medicine made from living cells through a highly complex and carefully monitored manufacturing process. Truxima (rituximab-abbs) is a biosimilar to Rituxan (rituximab) and is designed to treat adults with CD20-positive, B-cell non-Hodgkin lymphoma (NHL), a common subtype of NHL. It can be used as a single agent or in combination with chemotherapy. NHL refers to a group of cancers of the lymphatic system. These types of cancers can form anywhere ... Read More
Righting Injustice is published by the Beasley Allen Law Firm. If you are interested in a free legal consultation, please take a few moments to fill out the contact form with as many details as possible. The more information you provide us, the better we can evaluate your claim.